Cargando…
The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy
BACKGROUND: Neoadjuvant chemotherapy (NCT) increases the feasibility of surgical resection by downstaging large primary breast tumors and nodal involvement, which may result in surgical de-escalation and improved outcomes. This subanalysis from the Multi-Institutional Neo-adjuvant Therapy MammaPrint...
Autores principales: | Blumencranz, Peter, Habibi, Mehran, Shivers, Steve, Acs, Geza, Blumencranz, Lisa E., Yoder, Erin B., van der Baan, Bastiaan, Menicucci, Andrea R., Dauer, Patricia, Audeh, William, Cox, Charles E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625953/ https://www.ncbi.nlm.nih.gov/pubmed/37658272 http://dx.doi.org/10.1245/s10434-023-14027-9 |
Ejemplares similares
-
Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
por: Whitworth, Pat, et al.
Publicado: (2014) -
MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients
por: Haan, Josien C., et al.
Publicado: (2021) -
MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial
por: Soliman, Hatem, et al.
Publicado: (2020) -
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study
por: Wuerstlein, R., et al.
Publicado: (2019) -
Equivalence of MammaPrint array types in clinical trials and diagnostics
por: Beumer, Inès, et al.
Publicado: (2016)